DSIP Research: The Delta Sleep-Inducing Peptide and Its Unresolved Questions

What the published literature reports on DSIP, the delta sleep-inducing nonapeptide: its 1977 discovery, structure, transport studies and open questions.

Share

Delta sleep-inducing peptide, usually shortened to DSIP, is one of the older research peptides still discussed today. It was described in 1977, it has a short and well-defined sequence, and it generated hundreds of papers in the decades that followed. Yet a 2006 review in the Journal of Neurochemistry called it "a still unresolved riddle." This overview walks through what the published literature actually reports about DSIP: where it came from, how it is built, what transport and structural studies found, and why its biology remains uncertain. It is written for researchers and is not a guide to any use in people.

Discovery: a peptide isolated during induced sleep

DSIP came out of work by Guido Schoenenberger and Marcel Monnier's group in Basel. As later summarized by Sillard and colleagues, the peptide was characterized in rabbit cerebral venous blood plasma collected while sleep was induced by stimulating the thalamus. The group's 1977 paper in the Proceedings of the National Academy of Sciences reported the amino acid sequence and the results of infusing synthetic peptides into the brain ventricles of rabbits.

That study was carefully designed for its time. The authors synthesized DSIP, five possible metabolic fragments, two nonapeptide analogues with two amino acids exchanged, and a related tripeptide. All nine synthetic peptides were infused under double-blind conditions in a total of 58 rabbits, including controls, and the electroencephalogram (EEG) from cortical leads was analysed by fast Fourier transform. According to the abstract, only synthetic DSIP produced a significant and specific enhancement of delta and spindle EEG patterns. That result is the origin of the peptide's name.

Structure: a small, hydrophilic nonapeptide

DSIP is a linear nonapeptide with the sequence:

Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (one-letter code WAGGDASGE)

Its molecular weight is about 849 Da. With an aspartate and a C-terminal glutamate, it carries net negative charge at neutral pH and is quite hydrophilic.

A 1994 study in Biochemistry by Gray and colleagues at the University of Kansas used nuclear magnetic resonance (NMR), circular dichroism, infrared and fluorescence spectroscopy with molecular modelling to study DSIP in solution. They reported that the peptide exists in a dynamic equilibrium between unordered and folded structures. Residues 2-5 and 6-9 tended to form type I beta-turns in water, with a more ordered, helix-like structure appearing in 40% trifluoroethanol. Their infrared data suggested a beta-turn population of roughly 40% in aqueous solution.

For lab work, this matters. A short, flexible peptide like DSIP has no stable folded core to protect it, so its behaviour in an experiment depends heavily on solvent, pH and handling.

Transport studies: an unusual feature for a charged peptide

Much of the later interest in DSIP came from transport research rather than sleep research. Most peptides cross biological membranes poorly, and the Gray paper explicitly chose DSIP as a model because it is a charged, hydrophilic peptide reported to cross the blood-brain barrier.

Several published animal studies sit behind that description:

  • Monnier and colleagues, 1977 (Experientia). The Basel group reported that intravenous synthetic DSIP increased cortical delta activity and reduced motor activity in freely moving rabbits, which they interpreted as evidence that the peptide passes the blood-brain barrier.
  • Banks, Kastin, Coy and Angulo, 1986 (Brain Research Bulletin). Working in dogs, this group gave DSIP or one of four analogues intravenously and measured DSIP-like material in cerebrospinal fluid and blood over 60 minutes by radioimmunoassay. Entry into the cerebrospinal fluid correlated with plasma concentration, plasma half-life and peptide lipophilicity, but not with plasma protein binding or molecular weight. Combining the three significant factors gave a correlation of r = 0.813.

Two cautions apply when reading this work. First, several of these measurements rely on radioimmunoassay, which detects "DSIP-like" immunoreactivity rather than proving the intact nonapeptide is present. Second, these are animal models with specific sampling designs, so the findings describe transport behaviour under those conditions only.

The immunoreactivity puzzle

One reason DSIP biology is hard to pin down is that antibodies raised against it seem to recognize more than one molecule.

In 1993, Sillard and colleagues at the Karolinska Institutet reported in the European Journal of Biochemistry that they set out to identify the "large forms" of DSIP-like immunoreactivity seen in earlier studies. From porcine brain, they purified a 77-residue peptide they called DIP (DSIP-immunoreactive peptide). It was recognized by an antiserum raised against synthetic rabbit DSIP, yet its amino acid sequence was not related to DSIP. DIP contained a putative leucine-zipper motif, and its N-terminal region shared homology with a protein induced by transforming growth factor beta 1. The authors suggested a probable role in transcriptional regulation.

This finding is a useful reminder for anyone interpreting older immunoassay data: a signal from a DSIP antibody is not, by itself, proof of DSIP.

Why the field calls DSIP a riddle

Kovalzon and Strekalova's 2006 mini-review in the Journal of Neurochemistry is the most cited summary of where things stand. Its main points, as stated in the abstract:

  • The link between DSIP and sleep was never characterized further, partly because no DSIP gene, precursor protein or receptor has been isolated.
  • The hypothesis that DSIP is a natural sleep factor is therefore "extremely poorly documented and still weak."
  • DSIP's structure does not match any other known peptide family.
  • DSIP-like immunoreactivity is distributed in neurosecretory hypothalamic nuclei that are not particularly relevant to sleep regulation.
  • In the authors' own earlier rabbit and rat work, certain synthetic DSIP analogues, but not DSIP itself, showed significant slow-wave-sleep-promoting activity.

The authors proposed that an undiscovered DSIP-like peptide may account for at least part of the immunoreactivity and biological activity attributed to DSIP. That remains a hypothesis.

Earlier reviews by Graf and Kastin, in Neuroscience & Biobehavioral Reviews (1984) and Peptides (1986), catalogued the wide range of effects reported in the first decade of research. Read alongside the 2006 review, they show a field with many observations but no confirmed mechanism.

Practical notes for research labs

Because DSIP is short and flexible, material quality has an outsized effect on results:

  • Identity. Confirm the molecular weight by mass spectrometry against the expected mass for WAGGDASGE. See our guide to HPLC vs mass spectrometry.
  • Purity and content. HPLC purity and net peptide content answer different questions; our net content vs HPLC purity article shows why.
  • Tryptophan at position 1. Tryptophan is one of the residues most prone to oxidation, so protect material from light and air. Our guide to storing research peptides covers this.
  • Assay choice. Where possible, pair immunoassays with a method that confirms the intact sequence, given the cross-reactivity reported by Sillard and colleagues.
  • Analogue controls. Since analogues and fragments have behaved differently from the parent peptide in published work, include them as controls when the research question allows it.

Frequently asked questions

What is the DSIP sequence? Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, a nonapeptide of about 849 Da, as reported by Schoenenberger and Monnier in 1977.

Has a DSIP receptor been identified? Not according to the 2006 Kovalzon and Strekalova review, which lists the lack of an isolated gene, precursor protein or receptor as a central gap.

Is DIP the same as DSIP? No. DIP is a 77-residue peptide recognized by a DSIP antiserum, but its sequence is unrelated to DSIP.

Why is DSIP used in transport research? Because it is a small, charged, hydrophilic peptide that animal studies reported could reach the brain and cerebrospinal fluid, which makes it a model for studying how peptides cross barriers.

References

  • Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proceedings of the National Academy of Sciences USA. 1977;74(3):1282-1286. PMID: 265572. doi:10.1073/pnas.74.3.1282.
  • Monnier M, Dudler L, Gächter R, Schoenenberger GA. Transport of the synthetic peptide DSIP through the blood-brain barrier in rabbit. Experientia. 1977;33(12):1609-1610. PMID: 590449. doi:10.1007/BF01934026.
  • Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): a review. Neuroscience & Biobehavioral Reviews. 1984;8(1):83-93. PMID: 6145137. doi:10.1016/0149-7634(84)90022-8.
  • Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): an update. Peptides. 1986;7(6):1165-1187. PMID: 3550726. doi:10.1016/0196-9781(86)90148-8.
  • Banks WA, Kastin AJ, Coy DH, Angulo E. Entry of DSIP peptides into dog CSF: role of physicochemical and pharmacokinetic parameters. Brain Research Bulletin. 1986;17(2):155-158. PMID: 3768731. doi:10.1016/0361-9230(86)90111-5.
  • Sillard R, Schulz-Knappe P, Vogel P, Raida M, Bensch KW, Forssmann WG, Mutt V. A novel 77-residue peptide from porcine brain contains a leucine-zipper motif and is recognized by an antiserum to delta-sleep-inducing peptide. European Journal of Biochemistry. 1993;216(2):429-436. PMID: 8375381. doi:10.1111/j.1432-1033.1993.tb18160.x.
  • Gray RA, Vander Velde DG, Burke CJ, Manning MC, Middaugh CR, Borchardt RT. Delta-sleep-inducing peptide: solution conformational studies of a membrane-permeable peptide. Biochemistry. 1994;33(6):1323-1331. PMID: 8312250. doi:10.1021/bi00172a006.
  • Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. Journal of Neurochemistry. 2006;97(2):303-309. PMID: 16539679. doi:10.1111/j.1471-4159.2006.03693.x.

Research use only. All products sold by Morpheus Research are intended strictly for laboratory research and are not for human or veterinary consumption. Nothing in this article is medical advice, and no statement here is intended to diagnose, treat, cure or prevent any condition. Study findings are reported as published and should not be read as evidence of effects in people.